Arcutis Biotherapeutics, Inc. (ARQT) Financials

$13.67

$0.41 (3.09%)
Last update: 04:00 PM EST
Day's range
$13.24
Day's range
$13.99
$200M$200M$100M$100M$0$0-$100M-$100M-$200M-$200M-$300M-$300M-$400M-$400MEarning201820182019201920202020202120212022202220232023202420240%0%-2000%-2000%-4000%-4000%-6000%-6000%-8000%-8000%-10000%-10000%-12000%-12000%Profit Margin
Profit Margin
Revenue
Earnings

ARQT Income statement / Annual

Last year (2024), Arcutis Biotherapeutics, Inc.'s total revenue was $196.54 M, an increase of 229.74% from the previous year. In 2024, Arcutis Biotherapeutics, Inc.'s net income was -$140.04 M. See Arcutis Biotherapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Operating Revenue $196.54 M $59.61 M $3.69 M $0.00 $0.00 $0.00 $0.00 $0.00
Cost of Revenue $19.13 M $4.99 M $754.00 K $763.00 K $0.00 $0.00 $0.00 $0.00
Gross Profit $177.41 M $54.62 M $2.93 M -$763.00 K -$455.00 K -$195.00 K $0.00 $0.00
Gross Profit Ratio 0.9 0.92 0.8 0 0 0 0 0
Research and Development Expenses $76.42 M $110.58 M $182.44 M $145.56 M $115.31 M $36.52 M $17.94 M $3.41 M
General & Administrative Expenses $0.00 $0.00 $122.12 M $60.97 M $21.34 M $6.61 M $1.80 M $695.00 K
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $229.39 M $185.15 M $122.12 M $60.97 M $21.34 M $6.61 M $1.80 M $695.00 K
Other Expenses $0.00 $0.00 $5.82 M $173.00 K $967.00 K $1.14 M $480.00 K -$872.00 K
Operating Expenses $305.81 M $295.72 M $304.56 M $206.53 M $136.65 M $43.13 M $19.74 M $4.11 M
Cost And Expenses $324.94 M $300.71 M $305.31 M $206.53 M $136.65 M $43.13 M $19.74 M $4.11 M
Interest Income $0.00 $0.00 $9.83 M $173.00 K $967.00 K $1.14 M $0.00 $0.00
Interest Expense $27.17 M $29.71 M $15.65 M $0.00 $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $2.60 M $1.88 M $1.25 M $763.00 K $455.00 K $195.00 K $19.74 M $4.11 M
EBITDA -$109.63 M -$227.43 M -$294.55 M -$205.59 M -$135.22 M -$41.80 M $480.00 K -$872.00 K
EBITDA Ratio -0.56 -3.82 -79.91 0 0 0 0 0
Operating Income Ratio -0.65 -4.04 -81.83 0 0 0 0 0
Total Other Income/Expenses Net -$11.00 M -$17.93 M -$9.83 M $173.00 K $967.00 K $1.14 M $480.00 K -$872.00 K
Income Before Tax -$139.39 M -$259.03 M -$311.46 M -$206.36 M -$135.68 M -$42.00 M -$19.26 M -$4.98 M
Income Before Tax Ratio -0.71 -4.35 -84.5 0 0 0 0 0
Income Tax Expense $647.00 K $3.11 M $9.83 M -$454.00 K -$84.30 K $23.14 K -$480.00 K -$4.11 M
Net Income -$140.04 M -$262.14 M -$311.46 M -$206.36 M -$135.68 M -$42.00 M -$19.26 M -$4.98 M
Net Income Ratio -0.71 -4.4 -84.5 0 0 0 0 0
EPS -1.16 -3.78 -5.66 -4.17 -3.8 -1.1 -0.53 -0.14
EPS Diluted -1.16 -3.78 -5.66 -4.17 -3.8 -1.1 -0.53 -0.14
Weighted Average Shares Out $120.96 M $69.31 M $55.03 M $49.41 M $35.67 M $38.09 M $36.24 M $36.24 M
Weighted Average Shares Out Diluted $120.96 M $69.31 M $55.03 M $49.41 M $35.67 M $38.09 M $36.24 M $36.24 M
Link